FDA Fast Tracks new drug combo for treating Obstructive Sleep Apnea

Published On 2022-07-02 04:15 GMT   |   Update On 2022-07-02 09:00 GMT

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational drug AD109 for the treatment of obstructive sleep apnea (OSA). The new oral drug is a combination of atomoxetine and aroxybutynin which works by activating the upper airway dilator muscles and maintaining an open airway during sleep."Fast Track designation is a significant milestone in the...

Login or Register to read the full article

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational drug AD109 for the treatment of obstructive sleep apnea (OSA). The new oral drug is a combination of atomoxetine and aroxybutynin which works by activating the upper airway dilator muscles and maintaining an open airway during sleep.

"Fast Track designation is a significant milestone in the development of AD109 and provides an accelerated regulatory pathway that recognizes the urgent need for new pharmacologic treatments for OSA that are easier for people to tolerate," said Larry Miller, M.D., Chief Executive Officer of Apnimed. "Currently the vast majority of more than 35 million Americans who have OSA remain untreated despite the potential for serious health risks associated with the condition, including cardiovascular disease and diabetes.

We will continue to work closely with the FDA to support the development and review of AD109 beginning with the trial design for our Phase 3 program, which we anticipate initiating at the end of 2022."

FDA's Fast Track designation is intended to facilitate the development and expedite the review of new drugs to treat serious conditions and that fill an unmet medical need. The benefits of Fast Track designation include opportunities for frequent meetings with the FDA to discuss development plans, trial design, and data needed to support drug approval, as well as the ability to submit a New Drug Application (NDA) on a rolling basis, and eligibility for priority review, if relevant criteria are met.

Reference:

Apnimed granted FDA Fast Track designation for AD109, a novel first-in-class oral pharmacologic combination for the treatment of obstructive sleep apnea (OSA). News release. Apnimed. Accessed June 28, 2022. https://www.businesswire.com/news/home/20220628005075/en/Apnimed-Granted-FDA-Fast-Track-Designation-for-AD109-a-Novel-First-in-Class-Oral-Pharmacologic-Combination-for-the-Treatment-of-Obstructive-Sleep-Apnea-OSA

Tags:    
Advertisement

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News